VEGFA and amyotrophic lateral sclerosis: The delivery of VEGF directly or through viral vectors using different routes (intramuscular, intracerebroventricular, intrathecal or into the spinal cord parenchyma) considerably reduces the symptoms of the disease in murine models of ALS (Azzouz et al., 2004; Storkebaum et al., 2005; Dodge et al., 2010; Wang et al., 2016) and also protects motoneurons from excitotoxic-induced cell death (Tovar-y-Romo et al., 2007; Tovar-y-Romo and Tapia, 2010).